Storage: Store at or below -20 ºC.
Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 12.5 mg/mL with slight warming; soluble in water at 2 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A. Capecitabine, >99%. M.W. 359.35 C15H22FN3O6.
View the MSDS for this product
This drug has been approved in at least one country for use in patients with metastatic breast and colorectal cancers. Capecitabine is a pre-prodrug of 5-fluorouracil (5-FU). This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.;
NOTE: The capecitabine product sold by LC Laboratories is NOT Xeloda®, and is NOT for human use. After oral uptake, capecitabine is first metabolized to 5-deoxy-5-fluorocytidine (5-DFCR), which happens mainly in the liver by carboxyl-esterase.
Then 5-DFUR is converted to 5-FU intracellularly by thymidine phosphorylase, which is often expressed in tumor tissue. Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use./b>. Capecitabine is the active ingredient in the drug sold under the trade name Xeloda®. The metabolite is converted to 5-deoxy-5-fluoro-uridine (5-DFUR) by cytidine deaminase in liver and tumor tissue.